Metropolis HealthcareNSE:METROPOLIS +1.41%95 EBITDA Margin % is 27.38% as of Mar. 2026, which is 2% above its 10-year median of 26.84. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 82.84% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Metropolis Healthcare EBITDA Margin % Related Terms
Metropolis Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metropolis Healthcare (NSE:METROPOLIS) has a EBITDA Margin % of 27.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metropolis Healthcare and its competitors. This is near median its historical median of 26.84. Over the past decade, Metropolis Healthcare's EBITDA Margin % has ranged from 23.90 to 32.59. According to the industry distribution chart, Metropolis Healthcare ranks #35 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 17.2%.
Is Metropolis Healthcare's EBITDA Margin % too high?
Metropolis Healthcare's current EBITDA Margin % of 27.38% is near median its 10-year median of 26.84. Over the past 10 years, this metric has ranged from a low of 23.90 to a high of 32.59. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.22. Metropolis Healthcare's value of 27.38% is 425% above this industry median. Based on the distribution chart, Metropolis Healthcare ranks #35 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #35 out of 204 companies for EBITDA Margin %. This places Metropolis Healthcare in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.22. Metropolis Healthcare's value of 27.38% is 425% above this benchmark. Historically, Metropolis Healthcare's own EBITDA Margin % has ranged from 23.90 to 32.59 over the past decade. While the company's 10-year median is 26.84 vs. the industry median of 5.22, Metropolis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.22, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current EBITDA Margin % of 27.38% is 425% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current EBITDA Margin % is 27.38%, which is near median its own 10-year median of 26.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current EBITDA Margin % is 27.38%, which is near median its 10-year median of 26.84 and 425% above the Medical Diagnostics & Research industry median of 5.22. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current EBITDA Margin % is 27.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
EBITDA Margin %: 27.38% (near median its 10-year median of 26.84)
GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
Industry Position: 425% above the Medical Diagnostics & Research median (#35 of 204)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score
Get the complete analysis for NSE:METROPOLIS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
